JG
BMRN icon

Joel Greenblatt’s BioMarin Pharmaceuticals BMRN Stock Holding History

Joel Greenblatt’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.64M Sell
28,641
-145,450
-84% -$7.97M ﹤0.01% 1208
2026
Q1 		$9.83M Sell
174,091
-95,420
-35% -$5.56M 0.03% 700
2025
Q4 		$16M Buy
269,511
+4,179
+2% +$228K 0.06% 477
2025
Q3 		$14.4M Buy
265,332
+145,886
+122% +$8.34M 0.06% 455
2025
Q2 		$6.57M Buy
119,446
+71,977
+152% +$4.24M 0.04% 588
2025
Q1 		$3.36M Buy
47,469
+35,735
+305% +$2.4M 0.03% 642
2024
Q4 		$771K Sell
11,734
-11,661
-50% -$781K 0.01% 994
2024
Q3 		$1.64M Buy
+23,395
New +$1.96M 0.02% 783
2024
Q1 		– Sell
-2,446
Closed -$236K – 1380
2023
Q4 		$236K Sell
2,446
-1,610
-40% -$142K ﹤0.01% 1197
2023
Q3 		$359K Buy
+4,056
New +$361K 0.01% 1061
2023
Q2 		– Sell
-3,758
Closed -$365K – 1311
2023
Q1 		$365K Buy
+3,758
New +$390K 0.01% 1067
2021
Q4 		– Sell
-3,241
Closed -$250K – 1144
2021
Q3 		$250K Buy
+3,241
New +$256K 0.01% 898
2020
Q3 		– Sell
-5,842
Closed -$721K – 1035
2020
Q2 		$721K Sell
5,842
-5,178
-47% -$515K 0.02% 652
2020
Q1 		$931K Buy
11,020
+2,860
+35% +$246K 0.03% 565
2019
Q4 		$690K Buy
+8,160
New +$616K 0.01% 711
2017
Q4 		– Sell
-3,590
Closed -$334K – 936
2017
Q3 		$334K Buy
+3,590
New +$317K ﹤0.01% 779
2016
Q3 		– Sell
-3,144
Closed -$245K – 929
2016
Q2 		$245K Buy
+3,144
New +$267K ﹤0.01% 848
2015
Q2 		– Sell
-4,195
Closed -$523K – 926
2015
Q1 		$523K Buy
+4,195
New +$444K ﹤0.01% 683
2014
Q4 		– Sell
-3,885
Closed -$280K – 954
2014
Q3 		$280K Buy
+3,885
New +$255K ﹤0.01% 863

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Joel Greenblatt's BMRN Position: Q2 2026 in Review

Joel Greenblatt reduced its BioMarin Pharmaceuticals (BMRN) stake by 84% in Q2 2026, selling an estimated $7.97M and leaving 28,641 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #1208.

Joel Greenblatt first reported a position in BMRN in Q3 2014 and has held it in 19 quarters since. The position peaked at $16M in Q4 2025. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Joel Greenblatt held 28,641 shares of BioMarin Pharmaceuticals worth $1.64M as of Q2 2026.
  • Joel Greenblatt sold 145,450 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $7.97M.
  • BioMarin Pharmaceuticals made up ﹤0.01% of Joel Greenblatt's portfolio in Q2 2026, its #1208 holding.
  • Joel Greenblatt first reported a position in BioMarin Pharmaceuticals in Q3 2014 and has held it in 19 quarters since.
  • Joel Greenblatt's BioMarin Pharmaceuticals position peaked at $16M in Q4 2025.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.